Company research
Wave Life Sciences, Inc.
CIK 1631574Updated Oct 28, 2026
SecurityWVE · NASDAQ · equity
Name history
Wave Life Sciences Ltd. · through Jul 30, 2026Wave Life Sciences LTD. · through Jul 30, 2026WAVE Life Sciences Ltd. · through Jul 30, 2026Wave Life Sciences Pte Ltd · through Nov 2, 2015
WVE price & chart
Loading TradingView…
NASDAQ:WVE on TradingView ↗About the company
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s lead pipeline programs include obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 I148M liver disease (WVE-008), as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
In the news
Wave Life Sciences Announces Completion of Redomiciliation to Delaware ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
ARS filing
DEF 14A filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 241,378,000Source | 358,504,000Source | 558,321,000Source | 252,355,000Source | 208,818,000Source | 583,544,000Source | 288,343,000Source | 235,270,000Source | 638,499,000Source | 352,207,000Source | 274,949,000Source | 146,386,000Source |
| Property, Plant and Equipment, NetUSD | 8,196,000Source | 10,928,000Source | 6,833,000Source | 9,037,000Source | 11,783,000Source | 7,077,000Source | 9,566,000Source | 12,418,000Source | 7,405,000Source | 10,128,000Source | 13,084,000Source | 17,284,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 196,218,000Source | 310,948,000Source | 368,008,000Source | 208,481,000Source | 153,958,000Source | 544,591,000Source | 243,075,000Source | 180,922,000Source | 602,068,000Source | 302,078,000Source | 200,351,000Source | 88,497,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 10,000,000Source | 0Source | 888,000Source | 1,617,000Source | 1,290,000Source | 0Source | — | 0Source | 1,276,000Source | 1,422,000Source | 21,086,000Source | — |
| Assets, CurrentUSD | 215,488,000Source | 324,515,000Source | 507,508,000Source | 223,556,000Source | 172,075,000Source | 561,272,000Source | 257,976,000Source | 196,767,000Source | 614,814,000Source | 320,394,000Source | 235,373,000Source | 98,537,000Source |
| Operating Lease, Right-of-Use AssetUSD | 13,876,000Source | 19,119,000Source | 39,498,000Source | 15,250,000Source | 20,329,000Source | 10,994,000Source | 16,581,000Source | 21,502,000Source | 12,458,000Source | 17,870,000Source | 22,637,000Source | 26,843,000Source |
| Other Assets, NoncurrentUSD | 22,000Source | — | 667,000Source | 728,000Source | — | 386,000Source | 448,000Source | — | 16,000Source | 55,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 108,955,000Source | 208,990,000Source | 104,801,000Source | 105,215,000Source | 204,421,000Source | 71,814,000Source | 108,666,000Source | 202,007,000Source | 112,268,000Source | 134,818,000Source | 227,445,000Source | 183,603,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,223,721,000Source | 1,139,714,000Source | 1,627,209,000Source | 1,191,029,000Source | 950,530,000Source | 1,626,879,000Source | 1,179,336,000Source | 949,877,000Source | 1,616,478,000Source | 1,175,181,000Source | 935,367,000Source | 802,833,000Source |
| Additional Paid in CapitalUSD | 174,075,000Source | 153,196,000Source | 248,161,000Source | 167,603,000Source | 135,603,000Source | 237,428,000Source | 161,407,000Source | 132,118,000Source | 228,365,000Source | 156,454,000Source | 129,237,000Source | 119,442,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,273,057,000Source | -1,151,111,000Source | -1,421,678,000Source | -1,219,205,000Source | -1,089,331,000Source | -1,352,323,000Source | -1,168,736,000Source | -1,056,408,000Source | -1,326,236,000Source | -1,121,858,000Source | -1,024,850,000Source | -967,337,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -190,000Source | -159,000Source | -172,000Source | -161,000Source | -279,000Source | -254,000Source | -204,000Source | -198,000Source | -250,000Source | -262,000Source | -124,000Source | -29,000Source |
| Stockholders' Equity Attributable to ParentUSD | 124,549,000Source | 141,640,000Source | 453,520,000Source | 139,266,000Source | -3,477,000Source | 511,730,000Source | 171,803,000Source | 25,389,000Source | 518,357,000Source | 209,515,000Source | 39,630,000Source | -45,091,000Source |
| Liabilities and EquityUSD | 241,378,000Source | 358,504,000Source | 558,321,000Source | 252,355,000Source | 208,818,000Source | 583,544,000Source | 288,343,000Source | 235,270,000Source | 638,499,000Source | 352,207,000Source | 274,949,000Source | 146,386,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 85,896,000Source | 170,728,000Source | 50,815,000Source | 87,408,000Source | 173,128,000Source | 49,831,000Source | 87,367,000Source | 165,873,000Source | 95,065,000Source | 110,953,000Source | 186,440,000Source | 71,521,000Source |
| Operating Lease, Liability, CurrentUSD | 8,394,000Source | 7,398,000Source | 3,508,000Source | 8,136,000Source | 7,164,000Source | 8,328,000Source | 7,884,000Source | 6,936,000Source | 8,361,000Source | 7,638,000Source | 6,714,000Source | 5,496,000Source |
| Accounts Payable, CurrentUSD | 14,490,000Source | 12,781,000Source | 20,362,000Source | 14,664,000Source | 18,149,000Source | 19,064,000Source | 14,358,000Source | 11,730,000Source | 15,700,000Source | 16,262,000Source | 12,839,000Source | 16,915,000Source |
| Operating Lease, Liability, NoncurrentUSD | 11,378,000Source | 19,772,000Source | 40,082,000Source | 13,575,000Source | 21,711,000Source | 7,387,000Source | 15,715,000Source | 23,598,000Source | 9,405,000Source | 17,766,000Source | 25,404,000Source | 32,118,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 190,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 4,591,000Source | 2,825,000Source | 5,177,000Source | 3,176,000Source | 2,210,000Source | 4,854,000Source | 1,718,000Source | 1,754,000Source | 7,314,000Source | 4,551,000Source | 1,768,000Source | 3,516,000Source |
| Cash, Cash Equivalents, and Short-term Investments | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -26,087,000Source | -46,878,000Source | -204,378,000Source | -97,008,000Source | -57,513,000Source | -161,823,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -1,276,000Source | -1,422,000Source | -146,000Source | -19,664,000Source | 21,086,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 3,289,000Source | -2,052,000Source | -561,000Source | 3,421,000Source | -3,761,000Source | 9,348,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -59,553,000Source | -63,039,000Source | -187,493,000Source | -151,026,000Source | -19,431,000Source | -127,781,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -438,000Source | -165,000Source | -718,000Source | -938,000Source | -1,115,000Source | -1,255,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 438,000Source | 165,000Source | 718,000Source | 938,000Source | 1,115,000Source | 1,361,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 2,527,000Source | 4,155,000Source | 488,235,000Source | 253,890,000Source | 132,534,000Source | 67,188,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -57,468,000Source | -58,991,000Source | 300,036,000Source | 101,788,000Source | 111,893,000Source | -62,058,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 9,063,000Source | 4,953,000Source | 24,973,000Source | 13,141,000Source | 9,795,000Source | 17,194,000Source |
| DepreciationUSD | — | — | — | — | — | — | 841,000Source | 875,000Source | 3,440,000Source | 3,896,000Source | 5,000,000Source | 6,574,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | -12,000Source |
| General and Administrative ExpenseUSD | — | — | 18,087,000Source | 15,042,000Source | 24,781,000Source | 17,989,000Source | 22,104,000Source | 18,357,000Source | 75,331,000Source | 59,023,000Source | 51,292,000Source | 50,513,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | -677,000Source | 681,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -53,852,000Source | -61,780,000Source | -69,355,000Source | -50,469,000Source | -26,087,000Source | -46,878,000Source | -204,378,000Source | -97,008,000Source | -57,513,000Source | -161,823,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -204,378,000Source | -97,008,000Source | -57,513,000Source | -161,823,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,501,000Source | 2,135,000Source | 4,447,000Source | 2,290,000Source | 5,211,000Source | 2,926,000Source | 11,005,000Source | 13,395,000Source | 9,806,000Source | 1,578,000Source |
| Operating ExpensesUSD | — | — | 63,961,000Source | 56,239,000Source | 76,074,000Source | 61,458,000Source | 69,544,000Source | 58,979,000Source | 258,110,000Source | 218,705,000Source | 181,301,000Source | 166,369,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 324,000Source | 337,000Source | -275,000Source | -82,000Source | -80,000Source | 51,000Source | 527,000Source | 3,232,000Source | 1,878,000Source | 7,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 187,500,000Source | — | — | — | — | — | — | 93,574,000Source | 51,220,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,934,000Source | 2,451,000Source | 14,868,000Source | 2,979,000Source | 509,000Source | 223,000Source |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Investment Income, Interest | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Marketable Securities, Unrealized Gain (Loss) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | 2,272,000Source | 8,699,000Source | 38,246,000Source | 9,175,000Source | 42,727,000Source | 108,302,000Source | 113,305,000Source | 3,649,000Source |
| Operating Income (Loss)USD | — | — | -56,353,000Source | -63,915,000Source | -73,802,000Source | -52,759,000Source | -31,298,000Source | -49,804,000Source | -215,383,000Source | -110,403,000Source | -67,996,000Source | -162,720,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 324,000Source | 337,000Source | -275,000Source | -82,000Source | -80,000Source | 51,000Source | 527,000Source | 3,232,000Source | 1,878,000Source | 7,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -53,852,000Source | -61,780,000Source | -69,355,000Source | -50,469,000Source | -26,087,000Source | -46,878,000Source | -204,378,000Source | -97,008,000Source | -58,190,000Source | -161,142,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | -677,000Source | 681,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -53,852,000Source | -61,780,000Source | -69,355,000Source | -50,469,000Source | -26,087,000Source | -46,878,000Source | -204,378,000Source | -97,008,000Source | -57,513,000Source | -161,823,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.32Source | -0.47Source | -0.34Source | -0.31Source | -0.13Source | -0.29Source | -1.21Source | -0.7Source | -0.54Source | -2.05Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.32Source | -0.47Source | -0.34Source | -0.31Source | -0.13Source | -0.29Source | -1.21Source | -0.7Source | -0.54Source | -2.05Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 167,739,208Source | 132,563,467Source | 204,008,712Source | 163,987,640Source | 200,167,869Source | 162,572,026Source | 168,649,795Source | 138,277,468Source | 106,097,268Source | 78,855,810Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 167,739,208Source | 132,563,467Source | 204,008,712Source | 163,987,640Source | 200,167,869Source | 162,572,026Source | 168,649,795Source | 138,277,468Source | 106,097,268Source | 78,855,810Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | -677,000Source | 681,000Source |
| General and Administrative ExpenseUSD | — | — | 18,087,000Source | 15,042,000Source | 24,781,000Source | 17,989,000Source | 22,104,000Source | 18,357,000Source | 75,331,000Source | 59,023,000Source | 51,292,000Source | 50,513,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -204,378,000Source | -97,008,000Source | -57,513,000Source | -161,823,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,501,000Source | 2,135,000Source | 4,447,000Source | 2,290,000Source | 5,211,000Source | 2,926,000Source | 11,005,000Source | 13,395,000Source | 9,806,000Source | 1,578,000Source |
| Operating ExpensesUSD | — | — | 63,961,000Source | 56,239,000Source | 76,074,000Source | 61,458,000Source | 69,544,000Source | 58,979,000Source | 258,110,000Source | 218,705,000Source | 181,301,000Source | 166,369,000Source |
| Research and Development ExpenseUSD | — | — | 45,874,000Source | 41,197,000Source | 51,293,000Source | 43,469,000Source | 47,440,000Source | 40,622,000Source | 182,779,000Source | 159,682,000Source | 130,009,000Source | 115,856,000Source |
| Investment Income, Interest | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-233052
Filing attachments
d120442dex991.htm · 8-K · 2026-10-27
Exhibit 99.1 Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers Advancing WVE-007 (INHBE siRNA) across treatment settings: dosing ongoing in Phase 2a monotherapy clinical trial in individuals with higher BMI and comorbidities, initiated Phase 2a combination trial, and remain on track to initi…
Read attachment ↗d137806dex43.htm · POSASR · 2026-08-10
Exhibit 4.3 FORM OF SENIOR INDENTURE WAVE LIFE SCIENCES, INC. ISSUER and , TRUSTEE INDENTURE Dated as of, 20 Senior Debt Securities CROSS-REFERENCE TABLE1 Section of Section of Trust Indenture Act Section of Indenture of 1939, as amended ──────────────────────────────────────────────────── 310(a) 7.09 310(b) 7.08, 7.10 310(c) Inapplicable 311(a) …
Read attachment ↗d137806dex44.htm · POSASR · 2026-08-10
Exhibit 4.4 FORM OF SUBORDINATED DEBT SECURITIES INDENTURE WAVE LIFE SCIENCES, INC. INDENTURE DATED AS OF _________, 20__ TRUSTEE SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 6 SECTION 1.1 Definitions …
Read attachment ↗d177737dex991.htm · 8-K · 2026-07-30
EX-99.1 2 d177737dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007’s potential in MASH, type 2 diabetes, and other cardiometabolic diseases Phase 2 combination with incretin and post-incretin maintenance tri…
Read attachment ↗d177737dex992.htm · 8-K · 2026-07-30
EX-99.2 3 d177737dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Wave Life Sciences Corporate Presentation July 30, 2026 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activi…
Read attachment ↗d154261dex991.htm · 8-K · 2026-05-18
EX-99.1 2 d154261dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing On track for feedback from FDA on potential accelerated …
Read attachment ↗